Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • World
  • Users
  • Groups
Skins
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (Darkly)
  • No Skin
Collapse
Brand Logo
  1. Home
  2. Uncategorized
  3. DATE: February 06, 2026 at 04:30AMSOURCE: STAT HEALTH TECH

DATE: February 06, 2026 at 04:30AMSOURCE: STAT HEALTH TECH

Scheduled Pinned Locked Moved Uncategorized
healthcarehealthtechhealthcaretechhealthtechnologmedgadget
1 Posts 1 Posters 0 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Healthcare Tech RobotH This user is from outside of this forum
    Healthcare Tech RobotH This user is from outside of this forum
    Healthcare Tech Robot
    wrote last edited by
    #1

    DATE: February 06, 2026 at 04:30AM
    SOURCE: STAT HEALTH TECH

    TITLE: STAT+: Hims, other telehealth platforms push multi-cancer detection tests before evidence of benefit

    URL: https://www.statnews.com/2026/02/06/telehealth-firms-multi-cancer-tests-doctors-wary/?utm_campaign=rss

    A father pulls up in his car, waiting to pick up his kid. As he sits in the driver’s seat, he opens his phone. He smiles, and throws his head back with relief: “No cancer signal detected,” he reads, just as his son climbs in. 

    This scene appears in a Super Bowl ad that telehealth company Hims & Hers will run this weekend. Last year, Hims ran a controversial game-time clip promoting the company’s weight loss medications to more than 100 million viewers. This time, it’s using part of its minute-long slot to market one of its latest offerings: a multi-cancer early detection test called Galleri.

    Grail, the test’s developer, has faced many hurdles as it has worked to validate and market its blood-based test for detecting dozens of tumor types. Galleri and several competing multi-cancer tests have not been approved by the Food and Drug Administration, but their companies are able to market them as lab-developed tests — and increasingly, they have relied on telehealth platforms like Hims to prescribe their products to patients. 

    Continue to STAT+ to read the full story…

    URL: https://www.statnews.com/2026/02/06/telehealth-firms-multi-cancer-tests-doctors-wary/?utm_campaign=rss

    -------------------------------------------------

    STAT News reports "from the frontiers of health and medicine".

    Learn more at https://www.statnews.com/category/health-tech/ .

    See also their complete Mastodon account at @STAT .

    This robot is NOT affiliated with STAT news and merely rebroadcasts from their site. Responses posted here are not monitored.

    -------------------------------------------------

    Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
    .
    Healthcare security & privacy posts not related to IT or infosec are at @HIPAABot . Even so, they mix in some infosec with the legal & regulatory information..
    .
    -------------------------------------------------

    #healthcare #healthtech #healthcaretech #healthtechnology #medgadget #medicine #doctor

    1 Reply Last reply
    1
    0
    • #medicineT #medicine shared this topic
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    Powered by NodeBB Contributors
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • World
    • Users
    • Groups